M. Sc. Biochemistry, Ph.D. Life Science, Post-Doctoral Fellowship: Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, Texas/Doctoral Research Fellowship: Biomedical Sciences, Creighton University School of Medicine, Omaha, Nebraska/Visiting Scientist-Clinical Observer: Urology, New York Presbyterian-Weill Cornell Medical College, New York, NY, USA and Department of Clinical Research, IndiraIVF Hospital, Udaipur/Lucknow, India (Formerly)
Demystifying the “neuro-immune intersections” in the complex etiopathogenesis of neurological ailments primarily schizophrenia, obsessive compulsive disorder, Alzheimer’s disease and glioblastoma in ethnically disparate susceptible cohorts by immunotherapeutic targeting of Wnt/Frizzled-toll like receptors-autophagy biochemical/metabolic signaling cascades offers fascinating avenues in predictive biomarker development in the Covid-vaccination era [1-4]. CRISPR-Cas genetic engineering technology has emerged as an enigmatic modulator of complex human genetic diseases; precision-medicine based genome editing and detecting specific DNA/RNA sequences to gene expression control warrants future dynamic collaborations for in immuno-inflammatory disease(s)-management in the global Covid-19/Omicron pandemic and Covid-19 vaccination era. At The ability of CRISPR-Cas complexes to be meticulously programmed for targeting particular DNA loci, even when using catalytically inactive dCas-proteins is indeed intriguing; the sophisticated repertoire of naturally derived and bio-engineered dCas-proteins including fusion proteins is a promising toolbox for construction of functional synthetic genetic circuits for critical quantitative understanding of the basic principles governing gene expression regulation and functioning of living organisms [5,6]. In my expert opinion, the disproportionate share of psychosocial distress and neuro-behavioral deficits warrants a robust, evidence-based, pragmatic “public health-bioengineering CRISPR-Cas immunotherapeutic model” for design of pharmacological scaffolds, novel drugs and clinically validated predictive biomarkers for timely management of schizophrenia, obsessive compulsive disorder, Alzheimer’s disease and glioblastoma amongst genetically susceptible at-risk cohorts of asymptomatic vs borderline vs symptomatic heterogeneous subsets of ethnically disparate population-pools of distinct life-styles and socio-economic strata.
Saumya Pandey. CRISPR-Cas Gene-Editing for Precision-Medicine Based “Neuro-Oncogenomics” in Immunotherapeutic Targeting of Wnt/Frizzled-Toll Like Receptors-Autophagy: Cost-Effective Management of Schizophrenia, Obsessive Compulsive Disorder, Alzheimer’s Disease and Glioblastoma in Genetically Disparate Susceptible Population-Pools in in the Covid-19 Vaccination Era. EC Clinical and Medical Case Reports 6.2 (2023): 12-14.
© 2023 Saumya Pandey. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Open Access by ECronicon is
licensed under a Creative Commons Attribution
4.0 International License
Based on a work at www.ecronicon.net